100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43DK120175
Award Date
5/22/19
Completion Date
4/30/21
Dollars Obligated
$300K
Overview
Activity
5
Transactions
5
Subawards
Similar Awards
Federal Agency
National Institute of Diabetes and Digestive and Kidney Diseases
Awardee
Therasource LLC (NEHDGYYET4V5)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Manhasset, NY 11030, USA
Update #1
Update #2
A NEW THERAPY FOR ACUTE KIDNEY INJURY
Posted 5/22/19
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
A NEW THERAPY FOR ACUTE KIDNEY INJURY - PROJECT DESCRIPTION: THE PRIMARY OBJECTIVE OF THIS PROJECT IS TO DEMONSTRATE THE FEASIBILITY OF DEVELOPING C23 AS A NOVEL AND EFFECTIVE THERAPEUTIC FOR PATIENTS WITH ISCHEMIC ACUTE KIDNEY INJURY (AKI), A SIGNIFICANT CAUSE OF PROLONGED HOSPITALIZATION AND MORTALITY. ISCHEMIC AKI OFTEN COMPLICATES HEMORRHAGIC SHOCK, SEPTIC SHOCK, AND SURGERY. YET, DESPITE IT BEING A FREQUENT, LIFE-SHORTENING, AND COSTLY COMPLICATION, NO FDA-APPROVED DRUGS ARE CURRENTLY AVAILABLE TO TREAT PATIENTS WITH ISCHEMIC AKI. WE HAVE DISCOVERED THAT COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRP) ACTS AS A NOVEL DAMAGE-ASSOCIATED MOLECULAR PATTERN (DAMP) TO INCREASE INFLAMMATION AFTER ISCHEMIC INJURY. IN OUR PRELIMINARY STUDIES, WE SHOW THAT CIRP IS RELEASED INTO THE CIRCULATION AFTER RENAL ISCHEMIA AND REPERFUSION (RIR) AND PROMOTES THE DEVELOPMENT OF AKI. WE SCREENED CIRP-DERIVED SMALL PEPTIDES AND IDENTIFIED C23 TO HAVE HIGH AFFINITY FOR THE CIRP RECEPTOR AND INHIBIT CIRP ACTIVITIES. WE ALSO SHOW THAT ADMINISTRATION OF C23 AT THE BEGINNING OF REPERFUSION ATTENUATES RENAL INFLAMMATION AND DAMAGE. ADMINISTRATION OF C23 AT THE TIME OF REPERFUSION AFTER ISCHEMIA ALSO INCREASED THE SEVEN-DAY SURVIVAL OF MICE SUBJECTED TO RIR FROM 37% TO 70%. THEREFORE, WE HYPOTHESIZE THAT C23 CAN BE DEVELOPED AS A NEW AND EFFECTIVE DRUG TO IMPROVE RENAL FUNCTION AND PREVENT RENAL DAMAGE AFTER ISCHEMIC AKI. IN THIS PROJECT, WE WILL DEMONSTRATE THE FEASIBILITY OF DEVELOPING C23 TO TREAT ISCHEMIC AKI BY DETERMINING C23'S OPTIMAL DOSE TO IMPROVE RENAL FUNCTION AFTER RIR AND AFTER SEPSIS, C23'S THERAPEUTIC WINDOW TO IMPROVE SURVIVAL AFTER RIR AND AFTER SEPSIS, AND C23'S PHARMACOKINETIC AND SAFETY PROFILE IN HEALTHY ANIMALS. OUR FUTURE STEPS OF DRUG DEVELOPMENT (SBIR PHASE II AND BEYOND) INCLUDE COMPLETING PRECLINICAL STUDIES, ESTABLISHING ADME, ADVANCED PHARMACOKINETICS AND SAFETY STUDIES IN HEALTHY AND DISEASED ANIMALS, AND FILING AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH THE FDA TO INITIATE CLINICAL TRIALS. OUR ULTIMATE GOAL IS TO OBTAIN COMMERCIAL UTILIZATION OF C23 AS A SAFE AND EFFECTIVE DRUG FOR PATIENTS WITH ISCHEMIC AKI CAUSED BY RENAL HYPOPERFUSION.
$0
9/28/21
Not listed
A NEW THERAPY FOR ACUTE KIDNEY INJURY - PROJECT DESCRIPTION: THE PRIMARY OBJECTIVE OF THIS PROJECT IS TO DEMONSTRATE THE FEASIBILITY OF DEVELOPING C23 AS A NOVEL AND EFFECTIVE THERAPEUTIC FOR PATIENTS WITH ISCHEMIC ACUTE KIDNEY INJURY (AKI), A SIGNIFICANT CAUSE OF PROLONGED HOSPITALIZATION AND MORTALITY. ISCHEMIC AKI OFTEN COMPLICATES HEMORRHAGIC SHOCK, SEPTIC SHOCK, AND SURGERY. YET, DESPITE IT BEING A FREQUENT, LIFE-SHORTENING, AND COSTLY COMPLICATION, NO FDA-APPROVED DRUGS ARE CURRENTLY AVAILABLE TO TREAT PATIENTS WITH ISCHEMIC AKI. WE HAVE DISCOVERED THAT COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRP) ACTS AS A NOVEL DAMAGE-ASSOCIATED MOLECULAR PATTERN (DAMP) TO INCREASE INFLAMMATION AFTER ISCHEMIC INJURY. IN OUR PRELIMINARY STUDIES, WE SHOW THAT CIRP IS RELEASED INTO THE CIRCULATION AFTER RENAL ISCHEMIA AND REPERFUSION (RIR) AND PROMOTES THE DEVELOPMENT OF AKI. WE SCREENED CIRP-DERIVED SMALL PEPTIDES AND IDENTIFIED C23 TO HAVE HIGH AFFINITY FOR THE CIRP RECEPTOR AND INHIBIT CIRP ACTIVITIES. WE ALSO SHOW THAT ADMINISTRATION OF C23 AT THE BEGINNING OF REPERFUSION ATTENUATES RENAL INFLAMMATION AND DAMAGE. ADMINISTRATION OF C23 AT THE TIME OF REPERFUSION AFTER ISCHEMIA ALSO INCREASED THE SEVEN-DAY SURVIVAL OF MICE SUBJECTED TO RIR FROM 37% TO 70%. THEREFORE, WE HYPOTHESIZE THAT C23 CAN BE DEVELOPED AS A NEW AND EFFECTIVE DRUG TO IMPROVE RENAL FUNCTION AND PREVENT RENAL DAMAGE AFTER ISCHEMIC AKI. IN THIS PROJECT, WE WILL DEMONSTRATE THE FEASIBILITY OF DEVELOPING C23 TO TREAT ISCHEMIC AKI BY DETERMINING C23'S OPTIMAL DOSE TO IMPROVE RENAL FUNCTION AFTER RIR AND AFTER SEPSIS, C23'S THERAPEUTIC WINDOW TO IMPROVE SURVIVAL AFTER RIR AND AFTER SEPSIS, AND C23'S PHARMACOKINETIC AND SAFETY PROFILE IN HEALTHY ANIMALS. OUR FUTURE STEPS OF DRUG DEVELOPMENT (SBIR PHASE II AND BEYOND) INCLUDE COMPLETING PRECLINICAL STUDIES, ESTABLISHING ADME, ADVANCED PHARMACOKINETICS AND SAFETY STUDIES IN HEALTHY AND DISEASED ANIMALS, AND FILING AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH THE FDA TO INITIATE CLINICAL TRIALS. OUR ULTIMATE GOAL IS TO OBTAIN COMMERCIAL UTILIZATION OF C23 AS A SAFE AND EFFECTIVE DRUG FOR PATIENTS WITH ISCHEMIC AKI CAUSED BY RENAL HYPOPERFUSION.
$0
9/28/21
Not listed
A NEW THERAPY FOR ACUTE KIDNEY INJURY
$139.5k
5/1/20
Not listed
A NEW THERAPY FOR ACUTE KIDNEY INJURY
$0
1/22/20
Not listed
A NEW THERAPY FOR ACUTE KIDNEY INJURY
$160.5k
5/22/19